Sana and Mayo Clinic partner to advance a potential one-time cell therapy that could replace insulin for people with Type 1 diabetes.
Millions of people living with Type 1 diabetes have their lives built around maintenance – checking blood sugar, calculating meals, injecting insulin and constantly adjusting. It’s a routine that never really lets up. Now, Seattle-based Sana Biotechnology is making a move that challenges that entire model.
In a newly announced collaboration with Mayo Clinic, the company is pushing forward SC451, an experimental therapy designed to give the body back its ability to regulate blood sugar on its own [1]. Not manage it. Not assist it. The idea? Restore it. Replace what’s missing.
At the core of the partnership is SC451, a cell therapy built from pancreatic islet cells, the same kind that naturally produce insulin in healthy individuals. In Type 1 diabetes, these cells are destroyed by the immune system. Past attempts to replace them have run into a predictable wall: the body attacks the new cells too.
Sana’s approach tries to sidestep that problem. The company engineers these replacement cells so they can essentially “hide” from the immune system, allowing them to survive and keep producing insulin once transplanted. Think of it as replacing a broken part in a machine, but giving the new part an invisibility cloak so the system doesn’t reject it. This isn’t just a win for Type 1; it’s a proof-of-concept for the “hypoimmune” platform. If Sana can successfully cloak pancreatic cells, the same logic could eventually apply to any off-the-shelf cellular replacement – effectively swapping out aged or dysfunctional tissue across the body without the scorched-earth side effects of systemic immunosuppression.
The ambition is equally straightforward: a single treatment that could grant patients physiological autonomy, freeing them from both the mechanical burden of insulin injections and the chronic toxicity of immunosuppressant drugs.
Early data, while limited, hints at what’s possible. In one case, transplanted cells using Sana’s technology continued to function for over a year without being attacked, producing insulin and helping regulate blood sugar along the way.
“We are pleased to collaborate with Mayo Clinic as we advance SC451 toward a clinical trial that we are aiming to start this year,” said Steve Harr, Sana President and CEO. “Mayo Clinic’s longstanding commitment to patient-centered care, combined with a depth of expertise in transplant medicine and immunology, will help guide the development and delivery of SC451.”
Harr recently shared that data from a patient with Type 1 diabetes has fueled optimism regarding the transformative potential of SC451. He noted that pancreatic islets modified with the company’s hypoimmune platform technology successfully survived and remained functional for over a year without immunosuppression, suggesting a significant breakthrough in how the disease might be treated.
Why Mayo Clinic matters here
If Sana brings the technology, Mayo Clinic brings something just as critical: the ability to make it work in the real world.
The collaboration isn’t only about proving that SC451 can work; it’s about figuring out how to deliver it safely, consistently and at scale. That includes everything from how the cells are handled and transported, to how the procedure is performed, to how patients are monitored afterward. These details often determine whether breakthrough therapies succeed or fail.
Mayo will also contribute its expertise in clinical trial design and patient care, helping shape how the therapy is tested and, eventually, how it could be rolled out more broadly.
“Mayo Clinic is committed to advancing innovative therapies that address significant unmet patient needs, and through this collaboration, we seek to advance potential treatment options for patients with Type 1 diabetes,” said Dr Vijay Shah, Executive Dean of Research at Mayo Clinic.
Shah said that by merging specialized knowledge in cell therapy development and transplant immunology, the institution intends to conduct a thorough and disciplined evaluation of the investigational approach. He emphasized that the ultimate objective of this collaboration is to improve the quality of life for individuals with the condition.
The bigger picture: longevity isn’t just about living longer
It’s easy to perceive this as a story about diabetes, but it’s also a longevity story and a telling one. For years, much of healthcare has focused on managing chronic disease: keeping symptoms in check, slowing progression and extending life where possible. That approach has worked, but it comes with trade-offs, especially when treatment itself becomes a daily burden.
Longevity is, at its core, the maintenance of metabolic integrity. By restoring endogenous insulin regulation, we aren’t just ‘treating’ a condition; we are reinstating a youthful metabolic state that prevents the cascading damage – vascular aging, systemic inflammation, and organ decline – that chronic glucose volatility leaves in its wake.
What SC451 represents is a different philosophy. Instead of managing disease indefinitely, it aims to restore function at the cellular level – fixing what’s broken rather than working around it. Longevity, in this context, is about removing the friction disease introduces into those years. A person who no longer has to navigate the maze of insulin maintenance isn’t just living longer; they’re living differently.
There’s also a broader implication for medicine. If therapies like SC451 can be made safe, scalable and accessible, they could redefine how we think about chronic conditions. Now, as solvable biological problems.
Still, it’s early. The therapy has yet to enter full clinical trials, which Sana aims to begin as soon as this year. Many questions remain, from long-term safety to durability to cost and access. Cell therapies, for all their promise, are notoriously complex to manufacture and deliver.
Momentum is building, and that’s important – not just around SC451, but around the idea that engineered cells could become a new class of medicine. It’s a biotech company and one of the world’s leading medical institutions working together to figure out how that therapy could actually reach patients and change their lives. If that succeeds, the impact won’t stop at diabetes. It will ripple outward, into how we treat (and potentially resolve) some of the most persistent diseases of aging.